ARMY RANGER, 2005-2015 — MDMA-assisted therapy in the MAPS Phase 3 trial

Six combat deployments. Three Joint Task Force rotations. Diagnosed with severe PTSD in 2017, three different evidence-based therapies (Prolonged Exposure, Cognitive Processing Therapy, EMDR) over four years, all with partial but not durable response. I entered the MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for PTSD in 2021. The protocol: twelve weeks total, three eight-hour sessions with MDMA, interspersed with preparatory and integration sessions of standard talk therapy. Two co-therapists in the room for every dose session. Recordings of the sessions for my own review afterward. I am not going to describe the contents of the dose sessions. What happens during MDMA-assisted therapy is not the kind of experience that translates into a written story. I will say that the trauma did not disappear. What changed was my relationship to it. The PTSD checklist score I had been stable on for four years dropped by twenty-eight points in twelve weeks and remained at that level at the eighteen-month follow-up. FDA has not yet approved MDMA-assisted therapy. The trial results have been mixed in some published readouts. I am not writing a policy argument. I am writing as one veteran whose outcome was different inside that trial than four years of standard care had been outside it. I would do it again. I am watching the regulatory process carefully.